Skip to content

Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19

Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04543006
Acronym
PANCOLIN
Enrollment
170
Registered
2020-09-09
Start date
2020-09-08
Completion date
2021-12-31
Last updated
2020-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

neutralizing antibodies, long-term persistence

Brief summary

Covid-19 is associated with the onset of anti-SARS-CoV-2 antibodies; in a majority of patients, neutralizing antibodies are detected. However, the long-term persistence of such protective antibodies is not known. The investigators will explore patients with a proven Covid-19 (positive PCR) 6 and 12 months after the diagnosis to determine whether neutralizing antibodies are still detected. The investigators will determine whether this persistance varies according to * the severity of the Covid-19 * a treatment by steroids during the covid-19. This will help to anticipate whether a second wave of infection is possible in a non-naive population.

Detailed description

Covid-19 is associated with the onset of anti-SARS-CoV-2 antibodies; in a majority of patients, neutralizing antibodies are detected. However, the long-term persistence of such protective antibodies is not known. The investigators will explore adult patients with a proven Covid-19 (positive PCR) 6 and 12 months after the diagnosis to determine whether neutralizing antibodies are still detected. The investigators will determine whether this persistance varies according to * the severity of the Covid-19 (3 groups: no oxyegn therapy; oxygen therapy of less than 3L/min; oxygen therapy of 3L/min or more) * a treatment by steroids during the covid-19. Immunocompromised patients will be excluded.

Interventions

DIAGNOSTIC_TESTserology

blood sample of 10 ml twice (6 and 12 months after the Covid-19)

Sponsors

University Hospital, Grenoble
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

sample of patients 6 and 12 months after the acute disease

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* positive SARS-CoV-2

Exclusion criteria

* age under 18 * immunocompromised at the onset of Covid-19

Design outcomes

Primary

MeasureTime frameDescription
anti-SARS-CoV-2 neutralizing antibody titers1 dayTiter in plamsa of neutralizing anti-SARS-CoV-2 antibody

Contacts

Primary ContactOlivier Epaulard, MD,PhD
oepaulard@chu-grenoble.fr0033476765291

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026